Overview

High Dose Oral Omeprazole in High Risk UGIB

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world. After endoscopic treatment, proton pump inhibitor (PPI) is recommended to prevent re-bleeding. Intravenous PPI is recommended as a standard treatment.In the past, there were many trials showing the efficacy of high-dose oral PPI after endoscopic hemostasis but most were industrial sponsor which assessing an expensive PPI. Moreover, the number of patients in those studies were insufficient to confirm a non-inferiority outcome in term of rebleeding by using oral PPI. This study will evaluate a high-dose, local-made PPI (omeprazole) in peptic ulcer treatment after successful endoscopic hemostasis compared to standard IV PPI continuous drip.
Phase:
N/A
Details
Lead Sponsor:
King Chulalongkorn Memorial Hospital
Treatments:
Omeprazole